ArticleActa obstetricia et gynecologica Scandinavica2025
Carbon monoxide levels, smoking and adverse pregnancy outcomes.
Article in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbon monoxide levels, smoking and adverse pregnancy outcomes.Acta obstetricia et gynecologica Scandinavica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIdentifying pregnant smokers is crucial for cessation support and increased fetal surveillance, but some patients may not disclose their smoking. Biochemical markers like breath carbon monoxide (CO) can improve detection, yet the optimal CO threshold for predicting smoking-related risks remains unknown. Our objective was to assess the relationship between smoking, CO levels, and adverse pregnancy outcomes. MATERIAL AND
methodsThis retrospective cohort study analyzed 1 year of pregnancies (2023) in Oxford. Birthweight and adverse outcomes, small for gestational age (SGA), preterm birth (PTB), and extended perinatal mortality (EPM) were compared across CO categories and between self-reported smokers and nonsmokers with CO ≤2 and >2 ppm. Statistical analyses included changepoint analysis, one-way ANOVA, the Cochran-Armitage test for trend, binary logistic regression, and univariate linear regression.
resultsOf 6963 pregnancies, 5041 (72.4%) had recorded CO levels. The mean gestation at birth was 39 + 6 weeks, and the mean birthweight (BW) was 3439 g (560); the mean BW centile was 54.25 (28.00). The prevalence of SGA, PTB, and EPM was 6.7%, 5.0%, and 0.6%, respectively. CO levels were >2 ppm in 11.7% of the cohort, including 5.0% of self-reported non-smokers. Changepoint analysis identified 2 ppm as the threshold for mean birthweight. Above this level, each 1 ppm increase in CO was associated with a 69.35 g decrease in BW and a 3.15-point decrease in BW centile, indicating a dose-response relationship. Above 2 ppm, the odds of adverse outcomes were significantly increased: for SGA, OR 2.05-3.37; for PTB, OR 1.50-3.21; and for EPM, OR 2.52-4.22. Compared to non-smokers with low CO, smokers with high CO had the highest risk of all outcomes. Non-smokers with high CO had increased risks, but not significantly.
conclusionsAt a threshold of >2 ppm, CO was associated with lower mean birthweight and higher rates of SGA and PTB, with a dose-response relationship. Universal CO testing could help identify and quantify risk in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.